Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how to optimally treat this adverse effect.
Ajay K. Nooka, MD, MPH
Advertisement
Articles by Ajay K. Nooka, MD, MPH
Beyond progression-free survival, the combination of teclistamab and daratumumab hyaluronidase-fihj showed deep clinical responses, notes Ajay K. Nooka, MD, MPH.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
5